Company intelligence / Profile preview

MT-act

Montpellier, Occitania, Francemt-act.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

MT-act has developed a proprietary platform, MT-discover®, which delivers first-in-class small molecule drugs targeting uncharted tubulin-modifying enzymes. Their lead asset, MT-X01, aims to improve cardiac relaxation in hypertrophic cardiomyopathy without impairing contractility. The company remains preclinical and has not yet reported clinical results.

Therapeutic areas: CardiovascularNeurology
Modalities: small molecules
Industry: Biotech

Partnerships

Hosted on CNRS campus in Montpellier, France; access to CNRS resources and equipment.

Beyond the preview

Go deeper on MT-act.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-act.

Explore the full profile